BidaskClub upgraded shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from a hold rating to a buy rating in a report published on Thursday, July 6th.
Several other research firms have also commented on ACHN. Zacks Investment Research lowered Achillion Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, May 10th. Leerink Swann raised Achillion Pharmaceuticals from a market perform rating to an outperform rating and boosted their price target for the stock from $4.00 to $6.00 in a research report on Thursday, May 18th. TheStreet lowered Achillion Pharmaceuticals from a c- rating to a d rating in a research report on Wednesday, March 22nd. Robert W. Baird boosted their price target on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the stock an outperform rating in a research report on Monday, April 24th. Finally, Jefferies Group LLC reissued a hold rating on shares of Achillion Pharmaceuticals in a research report on Wednesday, April 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. Achillion Pharmaceuticals presently has an average rating of Buy and a consensus target price of $8.75.
Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded up 1.03% during mid-day trading on Thursday, hitting $3.94. 758,407 shares of the stock traded hands. The company’s market cap is $538.69 million. Achillion Pharmaceuticals has a one year low of $3.15 and a one year high of $9.49. The stock has a 50 day moving average price of $4.40 and a 200-day moving average price of $4.12.
WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/achillion-pharmaceuticals-inc-achn-upgraded-to-buy-at-bidaskclub-updated-updated-updated/1180287.html.
Several large investors have recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Achillion Pharmaceuticals during the fourth quarter worth $4,623,000. Renaissance Technologies LLC increased its position in shares of Achillion Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 945,189 shares of the biopharmaceutical company’s stock worth $3,904,000 after buying an additional 392,589 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Achillion Pharmaceuticals by 11.9% in the first quarter. Wells Fargo & Company MN now owns 215,820 shares of the biopharmaceutical company’s stock worth $908,000 after buying an additional 22,931 shares during the last quarter. Highbridge Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals during the first quarter worth approximately $149,000. Finally, Emory University increased its position in shares of Achillion Pharmaceuticals by 7.1% in the first quarter. Emory University now owns 486,438 shares of the biopharmaceutical company’s stock worth $2,048,000 after buying an additional 32,336 shares during the last quarter. Institutional investors and hedge funds own 71.24% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.